Sales show no signs of clumping
Mascara is a beauty essential that very few women will go without. After all, what woman doesn’t want long, lush, sexy lashes? Looking ahead, mascara sales show no signs of clumping.
According to data from SymphonyIRI Group, sales of mascara rose nearly 6% to nearly $600 million at food, drug and mass (excluding Walmart) for the 52 weeks ended Sept. 4.
Meanwhile, manufacturers continue to innovate and develop new mascaras that take lash length and volume to new heights.
For example, Maybelline New York launched in September its new Great Lash Lots of Lashes mascara, which features a little grabber brush. The heart-shaped elastomer brush is designed to simplify the application process and, in just one swipe, easily reach the inner and outer corners of the eye. The suggested retail price is $6.49.
For spring, Coty’s Rimmel London brand has created its new Volume Flash ScandalEyes Mascara. It is made with a supersized blend featuring triple the collagen and keratin of other mascaras on the market. Plus, the new MaxDensity brush is longer, wider, denser and 50% bigger than Rimmel’s biggest brush. The suggested retail price is $6.99.
No comments found
The eyes still have it and, judging by the numbers, so do the eyebrows.
Well-groomed brows can open up the face and help eyes pop, and according to data from SymphonyIRI Group, sales of eyebrow makeup rose nearly 5% during the 52 weeks ended Sept. 4 at food, drug and mass (excluding Walmart).
Meanwhile, sales of eyeliner rose nearly 7% during the same period. The continued development of eyeliner that promises to offer pinpoint precision and glides on easily will help further fuel sales.
It is likely that sales of both eyebrow makeup and eyeliner will continue to see growth going forward as women strive for sexy, sultry eyes that are bound to make him melt.
No comments found
Vitamin D meets the grade
Vitamin D has been one of the fastest-growing segments in the VMS market since 2010, a factor that has been in step with the number of positive clinical studies establishing the need for vitamin D supplementation.
One of the more recent clinicals, presented Oct. 2 at the 53rd annual meeting of the American Society for Radiation Oncology, found that more than three-quarters of cancer patients have insufficient levels of vitamin D, and the lowest levels are associated with more advanced cancer.
“Until recently, studies have not investigated whether vitamin D has an impact on the prognosis or course of cancer. Researchers are just starting to examine how vitamin D may impact specific features of cancer, such as the stage or extent of tumor spread, prognosis, recurrence or relapse of disease, and even sub-types of cancer,” stated Thomas Churilla, lead author of the study and a medical student at the Commonwealth Medical College in Scranton, Pa.